HSBC set a GBX 2,110 ($27.57) price target on GlaxoSmithKline (LON:GSK) in a research note published on Tuesday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Kepler Capital Markets set a GBX 1,600 ($20.91) price objective on shares of GlaxoSmithKline and gave the company a neutral rating in a research report on Tuesday, August 27th. Credit Suisse Group set a GBX 1,700 ($22.21) price objective on shares of GlaxoSmithKline and gave the company a neutral rating in a research report on Thursday, July 25th. Liberum Capital reissued a hold rating on shares of GlaxoSmithKline in a research report on Friday, August 23rd. JPMorgan Chase & Co. assumed coverage on shares of GlaxoSmithKline in a research report on Tuesday, August 13th. They issued a neutral rating and a GBX 1,700 ($22.21) price objective for the company. Finally, Jefferies Financial Group reissued a buy rating on shares of GlaxoSmithKline in a research report on Thursday, August 29th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of GBX 1,682.86 ($21.99).
GlaxoSmithKline stock opened at GBX 1,646.20 ($21.51) on Tuesday. The stock has a market cap of $82.91 billion and a price-to-earnings ratio of 18.54. The company has a debt-to-equity ratio of 1,127.74, a current ratio of 0.71 and a quick ratio of 0.44. GlaxoSmithKline has a 1 year low of GBX 1,408.80 ($18.41) and a 1 year high of GBX 1,767 ($23.09). The firm has a 50-day moving average of GBX 1,681.02 and a two-hundred day moving average of GBX 1,591.26.
In other GlaxoSmithKline news, insider Vivienne Cox purchased 434 shares of the stock in a transaction dated Wednesday, July 24th. The stock was purchased at an average price of GBX 1,654 ($21.61) per share, with a total value of £7,178.36 ($9,379.80). Insiders bought a total of 457 shares of company stock valued at $755,906 in the last ninety days.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Story: SEC Filing
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.